AVANT To Present At Rodman & Renshaw Techvest Healthcare Conference
Thursday October 16, 9:00 am ET
NEEDHAM, Mass.--(BUSINESS WIRE)--Oct. 16, 2003--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - News) today announced that Dr. Una S. Ryan, President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will present at the 5th Annual Rodman & Renshaw Techvest Healthcare Conference on Wednesday, October 22nd at 2:00 p.m., EDT. The conference is being held October 21-23 in Boston, MA at the Boston Marriott Long Wharf Hotel.
A live audio webcast of the presentation will be available online via the Investor Information area of AVANT's web site at avantimmune.com. An archive of the webcast will be available via AVANT's web site for 60 days following the event. A conference agenda will be posted on the Rodman & Renshaw web site at www.rodmanandrenshaw.com.
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a broad portfolio of vaccines addressing a wide range of applications including bacterial and viral diseases, chronic human disease, biodefense and food safety. These include single-dose, oral vaccines that protect against important disease-causing agents and a novel, proprietary vaccine candidate for cholesterol management. AVANT's goal is to demonstrate proof-of-concept for its products before leveraging their value through partnerships. Current collaborations encompass the development of an oral human rotavirus vaccine, vaccines to combat threats of biological warfare, and vaccines addressed to human food safety and animal health.
Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: avantimmune.com.
Contact:
AVANT Immunotherapeutics, Inc.
President and CEO
Una S. Ryan, Ph.D., 781-433-0771
or
AVANT Immunotherapeutics, Inc.
Chief Financial Officer
Avery W. Catlin, 781-433-0771
info@avantimmune.com
or
For Media:
Kureczka/Martin Associates
Joan Kureczka, 415-821-2413
jkureczka@aol.com
Source: AVANT Immunotherapeutics, Inc. |
